KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) EBT (2020 - 2023)

Historic EBT for AbCellera Biologics (ABCL) over the last 4 years, with Q4 2023 value amounting to -$48.6 million.

  • AbCellera Biologics' EBT fell 5472.43% to -$48.6 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$174.0 million, marking a year-over-year decrease of 17278.61%. This contributed to the annual value of -$200.4 million for FY2024, which is 1515.03% down from last year.
  • AbCellera Biologics' EBT amounted to -$48.6 million in Q4 2023, which was down 5472.43% from -$39.3 million recorded in Q3 2023.
  • AbCellera Biologics' EBT's 5-year high stood at $230.8 million during Q1 2022, with a 5-year trough of -$48.6 million in Q4 2023.
  • Over the past 4 years, AbCellera Biologics' median EBT value was -$2.4 million (recorded in 2020), while the average stood at $28.0 million.
  • Examining YoY changes over the last 5 years, AbCellera Biologics' EBT showed a top increase of 781557.57% in 2021 and a maximum decrease of 82729.3% in 2021.
  • AbCellera Biologics' EBT (Quarter) stood at $161.2 million in 2020, then crashed by 47.44% to $84.7 million in 2021, then crashed by 137.08% to -$31.4 million in 2022, then crashed by 54.72% to -$48.6 million in 2023.
  • Its EBT was -$48.6 million in Q4 2023, compared to -$39.3 million in Q3 2023 and -$38.0 million in Q2 2023.